{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(33)"],"submitter":["Ramalingam SS"],"funding":["Pfizer"],"pubmed_abstract":["Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer."],"journal":["Future oncology (London, England)"],"pagination":["2503-2508"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11537293"],"repository":["biostudies-literature"],"pubmed_title":["Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study."],"pmcid":["PMC11537293"],"pubmed_authors":["Carlisle JW","Ramalingam SS"],"additional_accession":[]},"is_claimable":false,"name":"Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.","description":"Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-04T18:53:54.856Z","creation":"2025-04-04T18:53:54.856Z"},"accession":"S-EPMC11537293","cross_references":{"pubmed":["39225598"],"doi":["10.1080/14796694.2024.2391270"]}}